Studies of the dependence-producing properties of GPA-1657, profadol, and propiram in man.
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D011431:Dextropropoxyphene / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D009019:Morphinans / Q000627:therapeutic use*; D009020:Morphine / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D009021:Morphine Dependence / Q000188:drug therapy*; D009269:Nalorphine / Q000494:pharmacology; D010423:Pentazocine / Q000627:therapeutic use; D010636:Phenols / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use; D010919:Placebos; D011680:Pupil / Q000187:drug effects; D011725:Pyridines / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use*; D011955:Receptors, Drug; D013375:Substance Withdrawal Syndrome; D019966:Substance-Related Disorders; D011795:Surveys and Questionnaires; D013997:Time Factors
D000700:Analgesics; D001952:Bridged-Ring Compounds; D009019:Morphinans; D010636:Phenols; D010880:Piperidines; D010919:Placebos; D011725:Pyridines; D011759:Pyrrolidines; D011955:Receptors, Drug; D009020:Morphine; D010423:Pentazocine; D011431:Dextropropoxyphene; D009269:Nalorphine